Predicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE)

This study is currently recruiting participants.

See

Contacts and Locations

Verified October 2015 by New England Research Institutes

Sponsor:

Collaborators:

IVC Filter Study Group Foundation (IDE Sponsor)

ALN Implants Chirurgicaux

B. Braun Interventional Systems, Inc

Bard Peripheral Vascular, Inc.

Cook Group Incorporated

Cordis Corporation

Rex Medical

Information provided by (Responsible Party):

New England Research Institutes

ClinicalTrials.gov Identifier:

NCT02381509

First received: March 2, 2015

Last updated: March 23, 2017

Last verified: October 2015

History of Changes

Purpose

PRESERVE is a multi-center, prospective, open-label, non-randomized investigation of commercially available IVC filters from 6 manufacturers placed in subjects for the prevention of pulmonary embolism (PE). This study will enroll approximately 1,800 IVC filter subjects at up to 60 sites in the US. All treated subjects will be evaluated at procedure, 3-months, 6-months (phone), 12-months, 18-months (phone), and 24-months post-procedure. The primary objective of this investigational device exemption (IDE) clinical investigation is to evaluate the safety and effectiveness of the commercially available IVC filters (retrievable and permanent) in subjects with clinical need for mechanical prophylaxis of PE with an IVC filter.

Condition	Intervention
Pulmonary Embolism	Device: IVC Filter


Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	Predicting the Safety and Effectiveness of Inferior Vena Cava Filters

Resource links provided by NLM:

MedlinePlus related topics: Pulmonary Embolism

U.S. FDA Resources

Further study details as provided by New England Research Institutes:

Primary Outcome Measures:

Composite safety endpoint of freedom from clinically significant perforation after successful filter placement, filter embolization, caval thrombotic occlusion, deep vein thrombosis, and perioperative serious adverse event [ Time Frame: within first 365 days (± 30 days) ]
Clinically significant perforation is defined as protrusion of filter legs through the wall of the IVC causing hemorrhage or hematoma or touching, impressing, or perforating another organ or that triggers the decision to remove the filter; resulting in an attempt to remove the IVC filter or requiring other intervention. Filter embolization is defined as movement of the filter or its components to a distant anatomic site completely out of the target zone after successful filter placement, confirmed by imaging. Caval thrombotic occlusion is defined as presence of an occluding thrombus in the IVC after filter insertion and documented by ultrasound (US), computed tomography (CT), magnetic resonance (MR) imaging, venography, or autopsy; this may be symptomatic or asymptomatic after successful filter placement. Deep vein thrombosis (DVT) is defined as new symptomatic DVT post-deployment, as determined by standard of care imaging. Serious adverse event is defined by ISO 14155.
Composite effectiveness endpoint of procedural and technical success without occurrence of clinically significant pulmonary embolism [ Time Frame: at 12-months in-situ or 1-month post-retrieval (whichever comes first) ]


Estimated Enrollment:	1800
Study Start Date:	October 2015
Estimated Study Completion Date:	May 2019
Estimated Primary Completion Date:	May 2018 (Final data collection date for primary outcome measure)

Groups/Cohorts	Assigned Interventions
IVC Filter IVC filter for the prevention of PE	Device: IVC Filter

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Subjects requiring the placement of one of 6 IVC filters for the prevention of PE.

Criteria

Inclusion Criteria:

Male or Female, age 18 years or older;
Requires IVC filter for prevention of pulmonary embolism (PE);
Provide written informed consent and written HIPAA authorization prior to initiation of study procedures;
Willing to comply with the specified follow-up

Exclusion Criteria:

Subject is unable to participate in study evaluations pre- and post-treatment
Known sensitivity to contrast or serious contrast reaction such as anaphylaxis for which premedication is known to be unsuccessful in alleviating symptoms

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02381509

Contacts


Contact: Jessica Lamp, BA	617-972-3140	jlamp@neriscience.com
Contact: Sandi Siami, MPH		ssiami@neriscience.com

Show 47 Study Locations

Sponsors and Collaborators

New England Research Institutes

IVC Filter Study Group Foundation (IDE Sponsor)

ALN Implants Chirurgicaux

B. Braun Interventional Systems, Inc

Bard Peripheral Vascular, Inc.

Cook Group Incorporated

Cordis Corporation

Rex Medical

Investigators


Study Chair:	David L. Gillespie, MD, RVT, FACS	Southcoast Health System
Study Chair:	Matt Johnson, MD	Indiana University School of Medicine

More Information


Responsible Party:	New England Research Institutes
ClinicalTrials.gov Identifier:	NCT02381509 History of Changes
Other Study ID Numbers:	M01482
Study First Received:	March 2, 2015
Last Updated:	March 23, 2017

Keywords provided by New England Research Institutes:


inferior vena cava filters

Additional relevant MeSH terms:


Embolism Pulmonary Embolism Embolism and Thrombosis Vascular Diseases	Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases

ClinicalTrials.gov processed this record on August 18, 2017

To Top